Hybrid closed-loop technology have shown that it improves glycemic control parameters, but the investigators do not have sufficient data at more than 6 months of follow-up, allowing us to describe the effectiveness of these systems in the long term. All MiniMed 780G system users from November 2020 to March 2022 were included (n=32) For every time points, there was a significant difference in Time In Range between the pre-AHCL and post-AHCL. Noted difference were +14.5% and, +10.8% at respectively 3 months and 1 year. No more hypoglycemia were identified. This "real-life" analysis shows that the algorithm is effective in improvement of metabolic control for T1 diabetic children and adolescents, at one year of follow-up. However, an effect of breathlessness is observed which underlined the need for a solid therapeutic education program.
Study Type
OBSERVATIONAL
Enrollment
32
Uhmontpellier
Montpellier, France
Glycated hemoglobin
Percentage of glycated hemoglobin measured by the MiniMed 780G system
Time frame: 1 year
Time spent in range Level with glucose levels within the norm
Time spent with glucose levels between 70 and 180 mg/dL
Time frame: 1 year
Time spent with glucose levels below range
Time spent with glucose levels inferior to 70mg/dL
Time frame: 1 year
Time spent with glucose levels above range
Time spent with glucose levels superior to 180 mg/dL
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.